Skip to main content
. 2021 Feb 1;131(3):e139333. doi: 10.1172/JCI139333

Figure 9. ATM mutations predict clinical benefits in patients with cancer treated with ICB therapy.

Figure 9

(A) ATM mutation frequencies across 10 human cancer types among 1661 patients with advanced-stage cancer who were treated with ICB therapy. (B) Frequencies of ATM alterations across different cancer types in the MSK-IMPACT cohort of 10,336 patients. Data were obtained from the cBioportal website. (C) Kaplan-Meier analysis of OS in ICB-treated patients with ATM mutations (red) versus those without (WT) (blue). (D) Kaplan-Meier analysis of OS of bladder cancer for patients with (red) or without (blue) ATM mutations. (E) Kaplan-Meier analysis of OS in ICB-treated patients with an ATM nonsense mutation (red) versus those without (blue). P values in C, D, and E were calculated by using the log-rank (Mantel-Cox) test.